The much-touted arrival of "precision medicine" promises tailored technologies that help individuals and may also reduce health care costs. New research shows how pregnancy screening can meet both of ...
AUSTIN, Texas, April 1, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, announced the results of a study1 to examine both total and donor-derived ...
SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of ...
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the American Journal of Transplantation (AJT) ...
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value ...
Austin, March 10, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The Cell-Free DNA (cfDNA) Testing Market size is valued at USD 10.85 Billion in 2025 and is expected to reach USD 39.43 Billion by ...
Researchers at the National Institutes of Health (NIH) found previously undetected cancers in 48.6% of pregnant people who had abnormal results for prenatal cell-free DNA (cfDNA) testing used to ...
In a recent study published in Cancer Discovery, researchers developed and validated a blood-based, cell-free deoxyribonucleic acid (cfDNA) fragmentome assay for lung cancer detection, which, if the ...
- The increasing demand for non-invasive testing methodologies and rising chronic disease incidence are driving the demand for the market. - Market Size – USD 3.80 billion in 2019, Market Growth - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results